Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Merck & Co., Inc.
  6. Financials
    MRK   US58933Y1055

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 198 695231 557206 957185 253--
Entreprise Value (EV)1 214 945247 453230 686205 815199 246194 014
P/E ratio 32,9x23,9x29,4x15,1x11,4x11,2x
Yield 2,60%2,48%3,03%3,54%3,91%4,11%
Capitalization / Revenue 4,70x4,94x4,31x3,81x3,30x3,35x
EV / Revenue 5,08x5,28x4,81x4,24x3,55x3,51x
EV / EBITDA 13,6x12,6x11,2x10,4x8,20x8,27x
Price to Book 7,42x9,00x8,18x5,74x4,62x3,87x
Nbr of stocks (in thousands) 2 600 3772 545 9842 530 0342 525 944--
Reference price (USD) 76,491,081,873,373,373,3
Announcement Date 02/01/201902/05/202002/04/2021---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 42 29446 84047 99448 57256 11755 247
EBITDA1 15 78119 57220 57019 74724 29123 472
Operating profit (EBIT)1 13 92615 92016 94517 65421 92721 526
Operating Margin 32,9%34,0%35,3%36,3%39,1%39,0%
Pre-Tax Profit (EBT)1 8 70111 4648 7918 57219 94020 123
Net income1 6 2209 8437 06712 37816 46517 034
Net margin 14,7%21,0%14,7%25,5%29,3%30,8%
EPS2 2,323,812,784,866,466,56
Dividend per Share2 1,992,262,482,602,873,01
Announcement Date 02/01/201902/05/202002/04/2021---
1 USD in Million
2 USD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales1 12 08011 40213 15413 14312 94013 083
EBITDA1 5 2204 6596 1114 703--
Operating profit (EBIT)1 4 2903 9695 3524 513--
Operating Margin 35,5%34,8%40,7%34,3%--
Pre-Tax Profit (EBT) -1 717----
Net income1 3 1791 2144 5673 422--
Net margin 26,3%10,6%34,7%26,0%--
EPS2 1,250,481,801,271,381,40
Dividend per Share ------
Announcement Date 04/29/202107/29/202110/28/2021---
1 USD in Million
2 USD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 16 25015 89623 72920 56213 9938 762
Net Cash position1 ------
Leverage (Debt / EBITDA) 1,03x0,81x1,15x1,04x0,58x0,37x
Free Cash Flow1 8 3079 9675 56912 71516 74217 924
ROE (Net Profit / Equities) 38,1%50,9%58,9%51,3%51,4%41,7%
Shareholders' equity1 16 33519 34812 00124 13032 06340 843
ROA (Net Profit / Asset) 13,6%11,8%17,1%14,4%18,4%18,6%
Assets1 45 63183 51741 23185 90589 29891 778
Book Value Per Share2 10,310,110,012,815,918,9
Cash Flow per Share2 4,085,214,046,867,428,06
Capex1 2 6153 4734 6843 6713 7323 473
Capex / Sales 6,18%7,41%9,76%7,56%6,65%6,29%
Announcement Date 02/01/201902/05/202002/04/2021---
1 USD in Million
2 USD
Analysis
Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022
Stock Pick
 MERCK AND COMPANY
Leader in oncology, modest valuation
Key data
Capitalization (USD) 185 252 728 266
Net sales (USD) 47 994 000 000
Number of employees 73 500
Sales / Employee (USD) 652 980
Free-Float 70,5%
Free-Float capitalization (USD) 130 695 470 994
Avg. Exchange 20 sessions (USD) 1 210 655 811
Average Daily Capital Traded 0,65%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA